Barclays raised the firm’s price target on West Pharmaceutical (WST) to $275 from $265 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the life science and diagnostic tools group as part of a Q1 preview. Barclays likes the setup for the sector but says it is “not without risk.” Sentiment is at all-time lows and Barclays still believes in the “last-cut thesis (for the most part),” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical expands Damastown, Dublin facility
- Orderly Leadership Transition and Reaffirmed 2026 Targets Underpin Buy Rating on West Pharmaceutical
- West Pharmaceutical says CEO Eric Green to retire
- Customer Concentration Risk: How Dependence on Key Accounts Threatens West Pharmaceutical’s Financial Stability
- West Pharmaceutical announces new $1B share repurchase program